Publications by authors named "Hieu Lam"

Claim this Profile
F
Fulbright as Opportunity for U.S. Nursing Educators and International Nursing Schools.
Lynda Boyer-Chu, Thu H T Huynh, Ngoan T N Nguyen, Tuyen K T Bui, Giang H L Ngo, Hieu H T Lam

J Nurs Educ· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer.
Shikhar Sharma, Chi-Yeh Chung, Sean Uryu, Jelena Petrovic, Joan Cao, Hieu Lam

Cell Chem Biol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance.
Kristen Jensen-Pergakes, John Tatlock, Karen A Maegley, Indrawan J McAlpine, Michele McTigue, Hieu Lam

Mol Cancer Ther· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retraction Note: Facile design of an ultra-thin broadband metamaterial absorber for C-band applications.
Nguyen Thi Quynh Hoa, Tran Sy Tuan, Lam Trung Hieu, Bach Long Giang

Sci Rep· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Facile design of an ultra-thin broadband metamaterial absorber for C-band applications.
Nguyen Thi Quynh Hoa, Tran Sy Tuan, Lam Trung Hieu, Bach Long Giang

Sci Rep· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance.
Ping Chen, Nathan V Lee, Wenyue Hu, Meirong Xu, Rose Ann Ferre, Hieu Lam

Mol Cancer Ther· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.
Helen Y Zou, Luc Friboulet, David P Kodack, Lars D Engstrom, Qiuhua Li, Hieu Lam, Justine L Lam

Cancer Cell· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.
Ted W Johnson, Paul F Richardson, Simon Bailey, Alexei Brooun, Benjamin J Burke, Hieu Lam, Justine L Lam

J Med Chem· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib.
Qinhua Huang, Ted W Johnson, Simon Bailey, Alexei Brooun, Kevin D Bunker, Hieu Lam, Justine L Lam

J Med Chem· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conformationally-restricted cyclic sulfones as potent and selective mTOR kinase inhibitors.
Kevin K-C Liu, Simon Bailey, Dac M Dinh, Hieu Lam, Chunze Li

Bioorg Med Chem Lett· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Azaindole hydroxamic acids are potent HIV-1 integrase inhibitors.
Michael B Plewe, Scott L Butler, Klaus R Dress, Qiyue Hu, Ted W Johnson, Hieu Lam

J Med Chem· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis